Q-omics provides the consensus-scored ART1 profile across patient tissues and cancer cell-line models. ART1 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ART1 is differentially expressed in 10, with the highest sampling consensus in HNSC. Additionally, ART1 RNA expression shows 11,071 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, HNSC, and THYM as cancer lineages where ART1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ART1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ART1 survival associations across molecular data types. ART1 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ART1 RNA expression–survival associations across cancer types. High ART1 expression shows unfavorable associations in LIHC, OV, MESO and CHOL, but favorable associations in KIRC and ESCA. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify KIRC as the clearest survival context for ART1 RNA expression.
This table summarizes ART1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 1. The strongest signals are observed in LUSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for ART1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ART1 shows lower tumor expression in HNSC, LUSC, LUAD, KICH, COAD and KIRP. The HNSC box plot shows higher ART1 RNA expression in normal versus tumor tissue (log2 FC = −0.995, t-test p = .002).
This table shows molecular features associated with ART1 in patient tissues and cancer cell lines. In patient samples, ART1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, ART1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in BONE and BLOOD_Leukemia.
